Current and emerging medical therapies for glaucoma

Bibliography

• VON GRAEFE A: Uber die wirking deriridetomie bei glaucom. Arch. Ophthalmol. 3:456–555.
   Google Scholar
• WEBER A: Uber calabar und seine therapeutische verwendung. Arch. Ophthalmol. 22: 215.
   Google Scholar
• TSAI JC, FORBES M: Medical management of glaucoma 2nd Edition. Professional Communications, West Islip, NY (2004).
   Google Scholar
• QUIGLEY HA: Number of people with glaucoma worldwide. Br. J. Ophthalmol. (1996) 80:389–393.
   PubMed Web of Science ®Google Scholar
• KASS MA, HEUER DK, HIGGINBOTHAM EJ et al.: The ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch. Ophthalmol. (2002) 120:701–713.
   PubMed Web of Science ®Google Scholar
• GORDON MO, BEISER JA, BRANDT JD et al.: The ocular hypertension treatment study: baseline factors that predict the onset of primary open-angle glaucoma. Arch. Ophthalmol. (2002) 120:714–720.
   PubMed Web of Science ®Google Scholar
• KLEIN BE, KLEIN R, SPONSEL WE et al.: Prevalence of glaucoma. The beaver dam eye study. Ophthalmology (1992) 99:1499–1504.
   PubMed Web of Science ®Google Scholar
• DIELEMANS I, VINGERLING JR, WOLFS RC, HOFMAN A, GROBBEE DE, DE JONG PT: The prevalence of primary open-angle glaucoma in a population-based study in the Netherlands. The Rotterdam study. Ophthalmology (1994) 101:1851–1855.
   PubMed Web of Science ®Google Scholar
• COLLABORATIVE NORMAL TENSION GLAUCOMA STUDY GROUP: The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am. J. Ophthalmol. (1998) 126:498–505.
   PubMed Web of Science ®Google Scholar
• HAYREH SS: Factors influencing blood flow in the optic nerve head. J. Glaucoma (1997) 6:412–425.
   PubMed Web of Science ®Google Scholar
• ASRANI S, ZEIMER R, WILENSKY J, GIESER D, VITALE S, LINDENMUTH K: Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J. Glaucoma (2000) 9:134–142.
   PubMed Web of Science ®Google Scholar
• BERGEA B, BODIN L, SVEDBERGH B: Impact of intraocular pressure regulation on visual fields in open-angle glaucoma. Ophthalmology (1999) 106:997–1004.
   PubMed Web of Science ®Google Scholar
• ZEIMER RC, WILENSKY JT, GIESER DK, VIANA MA: Association between intraocular pressure peaks and progression of visual field loss. Ophthalmology (1991) 98:64–69.
   PubMed Web of Science ®Google Scholar
• TSAI JC: Intraocular pressure. In: Fundamentals of Clinical Ophthalmology:Glaucoma. RA Hitchings (Ed). BMJ Books, London (2000):55–61.
   Google Scholar
• PATEL SC, SPAETH GL: Compliance in patients prescribed eyedrops for glaucoma. Ophthalmic Surg (1995) 26:233–236.
   PubMedGoogle Scholar
• CLAXTON AJ, CRAMER J, PIERCE C: A systematic review of the associations between dose regimens and medication compliance. Clin. Ther. (2001) 23:1296–1310.
   PubMed Web of Science ®Google Scholar
• TSAI JC, MCCLURE CA, RAMOS SE, SCHLUNDT DG, PICHERT JW: Compliance barriers in glaucoma: a systematic classification. J. Glaucoma (2003) 12:393–398.
   PubMed Web of Science ®Google Scholar
• ALWARD WL: Medical management of glaucoma. N EngL J. Med. (1998) 339:1298–1307.
   PubMed Web of Science ®Google Scholar
• STRAHLMAN E, TIPPING R, VOGEL R: A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol. International dorzolamide study group. Arch. Ophthalmol. (1995) 113:1009–1016.
   PubMed Web of Science ®Google Scholar
• SCHUMAN JS: Antiglaucoma medications: a review of safety and tolerability issues related to their use. Clin. Ther. (2000) 22:167–208.
   PubMed Web of Science ®Google Scholar
• TORTS CB, CAMRAS CB, YABLONSKI ME: Acute versus chronic effects of brimonidine on aqueous humor dynamics in ocular hypertensive patients. Am. J. Ophthalmol. (1999) 128:8–14.
   PubMed Web of Science ®Google Scholar
• KATZ LJ: Brimonidine tartrate 0.2% twice daily versus timolol 0.5% twice daily: 1-year results in glaucoma patients. Brimonidine study group. Am. J. Ophthalmol. (1999) 127:20–26.
   PubMed Web of Science ®Google Scholar
• LEBLANC RP: Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine study group 2. Ophthalmology (1998) 105:1960–1967.
   PubMed Web of Science ®Google Scholar
• KATZ LJ: Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension. J. Glaucoma (2002) 11:119–126.
   PubMed Web of Science ®Google Scholar
• BRANDT JD, VANDENBURGH AM, CHEN K, WHITCUP SM: Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP: a 3-month clinical trial. Ophthalmology (2001) 108:1023–1031.
   PubMed Web of Science ®Google Scholar
• CAMRAS CB: Comparison of latanoprostand timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States latanoprost study group. Ophthalmology (1996) 103: 138–147.
   Google Scholar
• NETLAND PA, LANDRY T, SULLIVAN EK et al.,: for the travoprost study group. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am. J. Ophthalmol. (2001) 132:472–484.
   PubMed Web of Science ®Google Scholar
• NORDMANN JP, MERTZ B, YANNOULIS NC, SCHWENNINGER C, KAPIK B, SHAMS N: A double-masked randomized comparison of the efficacy and safety of unoprostone with timolol and betaxolol in patients with primary open-angle glaucoma including pseudoexfoliation glaucoma or ocular hypertension. 6 month data. Am. J. Ophthalmol. (2002) 133:1–10.
   PubMed Web of Science ®Google Scholar
• SHERWOOD M, BRANDT J: Six-monthcomparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure. Surv. Ophthalmol. (2001) 45(Suppl. 4):5361–5368.
   Google Scholar
• WATSON P, STJERNSCHANTZ J: A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The latanoprost study group. Ophthalmology (1996) 103:126–137.
   PubMed Web of Science ®Google Scholar
• ORZALESI N, ROSSETTI L, BOTTOLI A, FUMAGALLI E, FOGAGNOLO P: The effect of latanoprost, brimonidine, and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Arch. Ophthalmol. (2003) 121:453–457.
   PubMed Web of Science ®Google Scholar
• STROHMAIER K, SNYDER E, DUBINER H, ADAMSONS I: The efficacy and safety of the dorzolamide-timolol combination versus the concomitant administration of its components. Ophthalmology (1999) 106:1–9.
   PubMed Web of Science ®Google Scholar
• PFEIFFER N: A comparison of the fixedcombination of latanoprost and timolol with its individual components. Graefis Arch. Clin. Exp. Ophthalmol. (2002) 240:893–899.
   PubMed Web of Science ®Google Scholar
• HIGGINBOTHAM EJ, FELDMAN R, STILES M, DUBINER H: Latanoprost and timolol combination therapy versus monotherapy: one-year randomized trial. Arch. Ophthalmol. (2002) 120:915–922.
   PubMed Web of Science ®Google Scholar
• DUBINER HB, SIRCY MD, LANDRY T et al.: Comparison of the diurnal ocular hypotensive efficacy of travoprost and latanoprost over a 44-hour period in patients with elevated intraocular pressure. Clin. Ther. (2004) 26:84–91.
   PubMed Web of Science ®Google Scholar
• WEINREB RN, LEVIN LA: Is neuroprotection a viable therapy for glaucoma? Arch. Ophthalmol. (1999) 117:1540–1544.
   Web of Science ®Google Scholar
• RING VOLD A: Epidemiology of the pseudo-exfoliation syndrome. Acta Ophthalmol. Scand. (1999) 77:371–375.
   PubMedGoogle Scholar
• LESKE MC, HEIJL A, HUSSEIN M, BENGTSSON B, HYMAN L, KOMAROFF E: Early Manifist Glaucoma Trial Group. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch. Ophthalmol. (2003) 121:48–56.
   PubMed Web of Science ®Google Scholar
• DELGADO MF, NGUYEN NT, COX TA et al.: Automated perimetry: a report by the american academy of ophthalmology. Ophthalmology (2002) 109:2362–2374.
   PubMed Web of Science ®Google Scholar
• HOOD DC, THIENPRASIDDHI P, GREENSTEIN VC et al.: Detecting early to mild glaucomatous damage: a comparison of the multifocal VEP and automated perimetry. Invest. Ophthalmol. Vis. Sci. (2004) 45:492–498.
   PubMed Web of Science ®Google Scholar
• THE AGIS INVESTIGATORS: Advanced glaucoma intervention study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am. J. Ophthalmol. (2000) 130:429–440.
   PubMed Web of Science ®Google Scholar
• COLLABORATIVE NORMAL-TENSION GLAUCOMA STUDY GROUP: Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am. J. Ophthalmol. (1998) 126:487–497.
   PubMed Web of Science ®Google Scholar
• HEDMAN K, ALM A, GROSS RL: Pooled-data analysis of three randomized, double-masked, six-month studies comparing intraocular pressure-reducing effects of latanoprost and timolol in patients with ocular hypertension. J. Glaucoma (2003) 12:463–465.
   PubMed Web of Science ®Google Scholar
• CAIVIRAS CB, HEDMAN K: Rate of response to latanoprost or timolol in patients with ocular hypertension or glaucoma. J. Glaucoma (2003) 12:466–469.
   PubMed Web of Science ®Google Scholar
• PARRISH RK, PALMBERG P, SHEU WP:A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am. J. Ophthalmol. (2003) 135:688–703.
   PubMed Web of Science ®Google Scholar
• NOECKER RS, DIRKS MS, CHOPLIN NT, BERNSTEIN P, BATOOSINGH AL, WHITCUP SM: A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am. J. Ophthalmol. (2003) 135:55–63.
   PubMed Web of Science ®Google Scholar
• KAUFMAN PL: The prostaglandin wars. Am. J. Ophthalmol. (2003) 136:727–728.
   PubMed Web of Science ®Google Scholar
• HEIJL A, LESKE MC, BENGTSSON B, HYMAN L, BENGTSSON B, HUSSEIN M: Reduction of intraocular pressure and glaucoma progression: results from the early manifest glaucoma trial. Arch. Ophthalmol. (2002) 120:1268–1279.
   PubMed Web of Science ®Google Scholar
• SCHUMER RA, PODOS SM: The nerve of glaucoma! Arch. Ophthalmol. (1994) 112:37–44.
   Web of Science ®Google Scholar
• WHEELER LA, GIL DW, WOLDEMUSSIE E: Role of alpha-2 adrenergic receptors in neuroprotection and glaucoma. Surv. Ophthalmol. (2001) 45(Suppl. 3):5290–5294.
   Google Scholar
• HARE W, WOLDEMUSSIE E, LAI R et al.: Efficacy and safety of memantine, an NMDA-type open-channel blocker, for reduction of retinal injury associated with experimental glaucoma in rat and monkey. Surv. Ophthalmol. (2001) 45\(Suppl. 3):5284–5289.
   Google Scholar
• SCHWARTZ M: Vaccination for glaucoma: dream or reality? Brain Res. Bull. (2004) 62:481–484.
   Google Scholar
• HARRIS A, AREND O, KAGEMANN L, GARRETT M, CHUNG HS, MARTIN B: Dorzolamide, visual function and ocular hemodynamics in normal-tension glaucoma. J. Ocul. Pharmacol. Ther. (1999) 15:189–197.
   PubMed Web of Science ®Google Scholar
• TAMAKI Y, ARAIE M, TOMITA K, NAGAHARA M: Effect of topical betaxolol on tissue circulation in the human optic nerve head./ Ocul. Pharmacol. Ther. (1999) 15:313–321.
   PubMed Web of Science ®Google Scholar
• MICHALK F, MICHELSON G, HARAZNY J, WERNER U, DANIEL WG, WERNER D: Single-dose nimodipine normalizes impaired retinal circulation in normal tension glaucoma. J. Glaucoma (2004) 13:158–162.
   PubMed Web of Science ®Google Scholar
• CHIEN FY, WANG RF, MITTAG TW, PODOS SM: Effect of WIN 55212-2, a cannabinoid receptor agonist, on aqueous humor dynamics in monkeys. Arch. Ophthalmol. (2003) 121:87–90.
   PubMed Web of Science ®Google Scholar
• MAY JA, MCLAUGHLIN MA, SHARIF NA, HELLBERG MR, DEAN TR: Evaluation of the ocular hypotensive response of serotonin 5-HT1A and 5-HT2 receptor ligands in conscious ocular hypertensive cynomolgus monkeys. J. Ocul Pharmacol Exp. Ther. (2003) 306:301–309.
   PubMed Web of Science ®Google Scholar
• RAUZ S, CHEUNG CM, WOOD PJ et al.: Inhibition of llbeta-hydroxysteroid dehydrogenase Type 1 lowers intraocular pressure in patients with ocular hypertension. QJM (2003) 96:481–490.
   PubMed Web of Science ®Google Scholar